Claimed effect · VIP (vasoactive intestinal peptide)

Does VIP (vasoactive intestinal peptide) help with 'Mould illness' / CIRS?

D
Grade D — no human evidenceNone controlled · effect size: not measurable
Short answerNo human evidence. As of 10 September 2026, only none controlled exist for VIP (vasoactive intestinal peptide) for 'Mould illness' / CIRS. The use it is most sold for online. No randomised trial exists; the diagnosis itself is not recognised by mainstream medicine. Claims rest on a single practitioner's uncontrolled case series.

What the studies show

The use it is most sold for online. No randomised trial exists; the diagnosis itself is not recognised by mainstream medicine. Claims rest on a single practitioner's uncontrolled case series.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

  1. 1

In context

Vasoactive intestinal peptide is a natural hormone that relaxes smooth muscle and blood vessels and dampens inflammation, made throughout the gut, lungs and nervous system. As the drug aviptadil it is licensed in the UK and some other countries — combined with phentolamine as an injection into the penis — for erectile dysfunction. Its pandemic moment came as an intravenous treatment for COVID-19 respiratory failure: the NIH-run TESICO trial of 461 patients was stopped for futility, with no improvement in outcomes or survival. The nasal-spray use promoted for 'chronic inflammatory response syndrome' from mould exposure has never been tested in a controlled trial.

VIP (vasoactive intestinal peptide) is licensed narrowly (ed, some countries); other uses unapproved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is VIP (vasoactive intestinal peptide) proven to help with 'Mould illness' / CIRS?
No. There is no human evidence for it (None controlled); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
The use it is most sold for online. No randomised trial exists; the diagnosis itself is not recognised by mainstream medicine. Claims rest on a single practitioner's uncontrolled case series.
Is VIP (vasoactive intestinal peptide) approved for this?
VIP (vasoactive intestinal peptide) is an approved medicine (Licensed narrowly (ED, some countries); other uses unapproved); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for VIP (vasoactive intestinal peptide)

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →